Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Menopause01:28

Menopause

3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

5.8K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
5.8K
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

362
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
362
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

730
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
730
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

6.3K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neighborhood-Level Racial and Ethnic Residential Segregation and Incidence of Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis.

Journal of the American Heart Association·2026
Same author

Association between Lipoprotein(a) and diet quality with cardiovascular disease risk: the multi-ethnic study of atherosclerosis.

American journal of preventive cardiology·2026
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

Disparities in Cardiovascular Medicine: Evidence Is Not Enough, Policy Change Is Essential.

Circulation·2026
Same author

Association of Subclinical Cardiac Remodeling With Incident Cancer in the MESA Cohort.

Journal of the American Heart Association·2026
Same author

Correction to: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026

Related Experiment Video

Updated: Jan 6, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.8K

Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to

Zoee D'Costa1, Emily Spertus2, Shipra Hingorany3

  • 1David Geffen School of Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. zdcosta@mednet.ucla.edu.

Current Atherosclerosis Reports
|October 9, 2025
PubMed
Summary

Menopause and hormone therapy impact cardiovascular risk. A personalized assessment framework is proposed to optimize safety and reduce heart disease risk during MHT initiation.

Keywords:
ASCVDAlgorithmCardiovascular riskHormoneMenopausal hormone therapy (MHT)Menopause

More Related Videos

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

16.0K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.2K

Related Experiment Videos

Last Updated: Jan 6, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.8K
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

16.0K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.2K

Area of Science:

  • Cardiology
  • Endocrinology
  • Women's Health

Background:

  • Menopause accelerates atherosclerotic heart disease risk due to hormonal, metabolic, and vascular changes.
  • Menopause and MHT influence cardiovascular risk factors and events like heart attack and stroke.

Purpose of the Study:

  • To discuss the cardiovascular risks associated with menopause and MHT.
  • To propose a framework for personalized cardiovascular risk assessment before initiating MHT.

Main Methods:

  • Review of clinical trial evidence on MHT formulations and cardiovascular outcomes.
  • Emphasis on personalized assessment including age, time since menopause, and baseline CV risk.
  • Inclusion of risk-enhancing factors and subclinical atherosclerosis imaging for comprehensive risk evaluation.

Main Results:

  • Early MHT formulations (oral CEE with MPA) showed increased cardiovascular risk, especially in older women.
  • Modern MHT (low-dose transdermal estrogen, micronized progesterone) demonstrates lower cardiovascular risk.
  • Personalized MHT initiation requires considering patient-specific factors and MHT characteristics.

Conclusions:

  • Menopause is a critical period for implementing cardiovascular disease prevention strategies.
  • A structured, individualized approach to MHT timing, formulation, and delivery can enhance cardiovascular safety.
  • Further research is needed to fully understand MHT's long-term cardiovascular effects.